Christelle Orlando: Type II Antithrombin Deficiency Frequently Underdiagnosed Due to Assay Limitations
Christelle Orlando, Coagulation Lab Expert at UZ Brussel and Vrije University Brussel, has shared a post on LinkedIn:
“New publication alert
I’m proud to present our recent paper on diagnosis on inherited antithrombin deficiency, published in Thrombosis and Haemostasis.
Diagnostic performance of commercial antithrombin activity assays: do we get what we expect?
In this paper, we compared the most commonly used antithrombin (AT) activity assays in their ability to diagnose inherited antithrombin deficiency, with a focus on type II AT deficiencies.
Key findings:
- Sensitive commercial AT activity assays are mandatory to identify AT deficiency
- Diagnostic sensitivity of commercial AT assays varies widely
- Some commercial AT activity assays are not suited for diagnosis of AT deficiency
- We report the first method comparison data from AT activity assays performed on CN6000 and sthemO301
- We describe two novel SERPINC1 variants responsible for type II AT deficiency
Take home messages:
This study highlights the poor performance of commercial antithrombin activity assays in their ability to detect type II AT deficiency. Our results suggest that this subtype of AT deficiency, a severe thrombotic disorder, is underdiagnosed.”
Title: Diagnostic Performance of Commercial Antithrombin Activity Assays: Do We Get What We Expect?
Authors: Christelle Orlando, Céline Drèze, Anton Evenepoel, Sara Seneca, Kristin Jochmans
Read the full paper here.
Stay updated with Hemostasis Today.
-
Sep 13, 2025, 10:49Ranjeet Ajmani Invites You To Join The AABB-AATM Joint Webinar on Plasma Fractionation
-
Sep 13, 2025, 10:23Peter Lenting at BIC 2025: Fantastic Lecture on FVIII Mimetics
-
Sep 13, 2025, 09:54Cihan Ay: ISTH 2026 In Planning!
-
Sep 12, 2025, 06:39Chokri Ben Lamine: Approach to Intra-Operative Bleeding in G6P Deficiency – Key Causes and Management
-
Sep 11, 2025, 15:42The True Price of Gene Therapy: Breaking Down Beqvez’s $3.5M Cost and What Really Drives It
-
Sep 13, 2025, 10:36Drug-Induced Immune Haemolytic Anaemia: A Decade Review by Abdul Mannan
-
Sep 13, 2025, 09:44Christelle Orlando: Type II Antithrombin Deficiency Frequently Underdiagnosed Due to Assay Limitations
-
Sep 13, 2025, 01:37Flora Peyvandi on Iron Deficiency in Mild to Moderate Bleeding Disorders
-
Sep 12, 2025, 07:28Lauren Murphy: Platelets as DNA “Sponges”
-
Sep 12, 2025, 03:38Haematologica Early View: Omid Seidizadeh Explores Genetics Behind Clinical Variability in Type 2 VWD
-
Sep 12, 2025, 15:21Christian Schäfer: INR Self-Management Has Officially Been Given Class IA Status in the ESC Guidelines
-
Sep 9, 2025, 20:15Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
-
Sep 8, 2025, 14:24Von Willebrand Factor as a Therapeutic Target․ From Development to Clinical Application
-
Sep 8, 2025, 02:35Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
-
Sep 7, 2025, 14:16Mary Kiige: Biological Hemoglobin Oxygen Carrier as a Lifesaving Oxygen Bridge
-
Sep 13, 2025, 13:34Brian O Mahony on 5-Year Roctavian Gene Therapy Data from BIC2025
-
Sep 13, 2025, 10:55José Antonio García Erce: Platelet Program for the Management of the Patient's Blood
-
Sep 12, 2025, 07:54Aurelio Maggio Thanks Contributors to Webinar on Advanced Treatments in Rare Blood Disorders
-
Sep 12, 2025, 07:20Women for Their Health: Paige Bingham on Boston Scientific's Initiative ''Close the Gap'' Act During AFib Awareness Month
-
Sep 11, 2025, 15:27Postpartum Haemorrhage: In Kenya, More than 120 Mothers Die for Every 100,000 Live Births